An Underrated Miracle Drug (for many) — Key Takeaways
Substack
An Underrated Miracle Drug (for many)
Dalton (Analyze & Optimize)Jun 19, 2026
Read the originalLow-dose naltrexone (1–5 mg) blocks TLR4-driven inflammation and upregulates endorphins, showing clinical improvement in 74.5% of IBD patients and outperforming conventional treatment for psoriasis severity scores.
Key takeaways
Low-dose naltrexone (1–5 mg) reduces systemic inflammation via two mechanisms
Low-dose naltrexone (1–5 mg) reduces systemic inflammation via two mechanisms
- Blocks mu opioid receptor → upregulates endogenous endorphins with anti-inflammatory effects on immune cells.
- Antagonizes TLR4, the primary receptor for bacterial endotoxin-driven inflammation across all tissues.
LDN produced 74.5% clinical improvement and 25.5% remission in IBD patients
LDN produced 74.5% clinical improvement and 25.5% remission in IBD patients
- Trial of IBD patients on LDN showed clinical improvement in ~3/4 of subjects and full remission in ~1/4.
- LDN also reduced ER stress and improved cell migration — both markers of gut tissue repair.
LDN outperformed conventional treatment on psoriasis severity scores
LDN outperformed conventional treatment on psoriasis severity scores
- Both BSA and PASI scores — standard psoriasis severity measures — were reduced more with LDN than standard care.
This Dig holds the full set of insights, 4 flashcards, and 2 quotes — free in Homestake.
Unlock this Dig freeFree forever · No credit card required
In this piece
- LDN Mechanism: How Low Doses Rewire Immune Signaling
- IBD Trial Results
- Chronic Fatigue Syndrome: Patient Recovery Case
- Psoriasis: LDN Outperforms Conventional Treatment
- Physician Endorsements from Clinical Practice
- Evidence Limitations and Safety Summary
This page is a partial, transformative summary produced by Homestake. All rights to the original content remain with its creator — please support them at the source link above.
